PharmAla Licenses U.S. Rights to MDMA Therapeutic ALA-002 in $100M+ Deal with Jupiter Neurosciences — PharmAla Biotech Holdings Inc.

Event summary

PharmAla has signed a term sheet to license exclusive U.S. rights to ALA-002, its next-generation MDMA therapeutic, to Jupiter Neurosciences in a deal valued at over $100 million.
The transaction includes a $3.33 million upfront payment, comprising $1.5 million in cash and $1.83 million in Jupiter stock, with additional milestone payments and royalties.
PharmAla retains all rights to ALA-002 outside the U.S., including its commercial presence through Cortexa in Australia.
ALA-002 is a patented, non-racemic MDMA formulation recognized by the FDA as a Novel Chemical Entity, designed for improved cardiovascular safety and reduced abuse liability.
The deal is subject to due diligence, definitive agreement execution, and regulatory approvals, with a 90-day closing period.

The big picture

This deal positions ALA-002 for dedicated U.S. development and commercialization through a NASDAQ-listed CNS specialist, while allowing PharmAla to focus on its global MDXX strategy. The transaction validates PharmAla's NCE patent strategy and provides non-dilutive capital, aligning with broader industry trends toward psychedelic therapeutics for mental health conditions. The $100M+ valuation underscores the growing market potential for next-generation MDMA formulations.

What we're watching

Regulatory Validation: Whether the FDA's recognition of ALA-002 as a Novel Chemical Entity will accelerate its development and approval process.
Execution Risk: The pace at which PharmAla and Jupiter can finalize the definitive agreement and meet the 90-day closing deadline.
Market Expansion: How PharmAla's retention of ex-U.S. rights to ALA-002 will impact its commercial operations through Cortexa in Australia and other global markets.